CARTER P J. Potent antibody therapeutics by design. Nat Rev Immunol, 2006, 6(4):343-357. HOOGENBOOM H R. Selecting and screening recombinant antibody libraries. Nat Biotechnol, 2005, 23:1105-1116. LONBERG N. Human antibodies from transgenic animals. Nat Biotechnol, 2005, 23:1117-1125. ADAMS G P, WEINER L M. Monoclonal antibody therapy of cancer. Nat Biotechnol, 2005, 23:1147-1157. REICHERT J M, ROSENSWEIG C J, FADEN L B, et al. Monoclonal antibody successes in the clinic. Nat Biotechnol, 2005, 23:1073-1078. KIM S J, PARK Y, HONG H J, et al. Antibody engineering for the development of therapeutic antibodies. Mol Cells, 2005, 20(1):17-29. CARSON K L. Flexibility-the guiding principle for antibody manufacturing. Nat Biotechnol, 2005, 23:1054-1058. BIRCH J R, RACHER A J. Antibody production. Adv Drug Deliv Rev, 2006, 58:671-85. LIU C X, ZHONG D F, HAN G Z, et al. Practical Pharmacokinetics(实用药物动力学). Beijing: Chinese Pharmaceutical Science and Technology Press, 2003. TANG C M, LIU X W, SONG H F, et al. Pharmacokinetics of Biotech Drugs(生物技术药物药代动力学). Beijing: Chemical Industry Press, 2004. LIU C X. Course on Drug Evaluation(药物评价学). Beijing:Chemical Industry Press. June 2005. BERND M. Pharmacokinetics and Pharmacodynamics of Biotech Drugs. Germany:Weinheim:Wiley-VCH, 2006:5-12. MEIBOHM B, DERENDORF H. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. Int J Clin Pharmaco Ther, 1997, 35:401-413. DERENDORF H, MEIBOHM B. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives. Pharm Res, 1999, 16(2):176-185. PUTNAM W S, PRABHU S, ZHENG Y, et al. Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies. Trends Biotechnol, 2010, 28(10):509-516. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonized Tripartite Guideline E10, Choice Of Control Group And Related Issues In Clinical Trials (CPMP/ICH/364/96) 2000, ICH, Geneva. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonized Tripartite Guideline E4, Dose-Response Information to Support Drug Registration (CPMP/ICH/378/95) 1994, ICH, Geneva. LEWIS R M, COSENZA M E. Summary of DIA Workshop: Comparability Challenges: Regulatory and Scientific Issues in the Assessment of Biopharmaceuticals. Drug Information J, 2010, 44(4): 485-504. The European Agency for the Evaluation of Medicinal Products. Guideline on Comparability of Biotechnology-derived Medicinal Products After a Change in the Manufacturing Process: Non-clinical and Clinical Issues (EMEA/CHMP/BMWP/101695/2006) 2007, EMA, London. RAU R. Adalimumab (a fully human anti-tumour necrosis factor a monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann Rheum Dis, 2002, 61(S1):70-73. VANDE PUTTE LBA, SALTELD J, KAYMAKCALAN Z. (2003) Adalimumab. In: Moreland LW Emery P (Eds.), TNF-Inhibition in the Treatment of Rheumatoid Arthritis. Martin Dunitz, London, PP 71-93 GRANNEMAN R G, ZHANG Y, Noetersheuser P A, et al. Pharmacokinetic/pharmacodynamic (PK/PD) relationships of adalimumab (Humira, Abbott) in rheumatoid arthritis patients during Phase II/III clinical trials . Arthritis Rheum, 2003, 48 (Suppl.):140-144. SCHIFF M H, BURMESTER G R, KENT J D, et al. Safety analyses of adalimumab (Humira) in global clinical trials with US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis, 2006, 65(7):889-894. REBELLO P, CWYNARSKI K, VARUGHESE M, et al. Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy, 2001, 3(4):261-267. CAMPATH (Alemtuzumab) product information 2004. HALE G, REBELLO P, BRETTMAN LR, et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood, 2004, 104(4):948-955. MORTENSEN DL, WALICKE PA, WANG X, et al. Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis. J Clin Pharmacol, 2005, 45(3): 286-298. BAUER R J, DEDRICK R L, WHITE M L, et al. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hull24 in human subjects with psoriasis. J Pharmacokinet Biopharm, 1999, 27(4): 397-400. COFFEY G P, STEFANICH E, PALMIERI S, et al. In vitro internalization, intracellular transport and clearance of efalizumab (Raptiva) by humanT-cells. J Pharmacol Exp Ther, 2004, 310:896-904. SUN Y, YU J, JOSHI A, et al. population pharmacokinetics of Efalizumab (humanized monoclonal CD Ⅱ antibody) following long term subcutaneous weekly dosing in psoriasis subjects. J Clin Pharmacol, 2005, 45:468-476. GOTTLIEB A B, HAMILTON T T, WALICKE P A, et al. Efficacy, safety and pharmacokinetic outcomes observed in patients with plaque psoriasis during longterm efalizumab therapy: results from an open-label trial.International Investigative Dermatology Meeting April 30-May 4, 2003 Miami Beach Florida, Poster 2003, 379. SMITH S L. Ten years of Orthoclone OKT3 (muromonab-CD3): a review. J Transpl Coord, 1996, 6(3):109-119. GOTTLIEB AB, MASUD S, RAMAMURTHI R. et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol, 2003, 48(1): 68-75. CORNILLIE F, SHEALY D, D’HAENS G, et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohns disease. Aliment Pharmacol Ther, 2001, 15(4): 463-473. CLAIR E W, WAGNER C L, FASANMADE A A, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT. A multicenter, randomized. Double-blind. Placebo-controlledtrial. Arthritis Rheum, 2002, 46(6):1451-1459. MARKHAM A, LAMB H M. Infliximab: A review of its use in the management of rheumatoid arthritis. Drugs, 2000, 59(6):1341-1359. WILDE M I, GOA L G. Muromonab CD3. A reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drug, 1996, 51(5):865-894. ABRAMOWICZ D, GOLDMAN M, MAT O, et al. OKT3 serum levels as a guide for prophylactic therapy: A pilot study in kidney transplant recipients. Transpl Int, 1994, 7(4):258-263. BROUGHAN T A, VALENZUELA R, ESCORCIA E, et al. Mouse antibody-coated lymphocytes during OKT3 therapy in liver transplantation. Clin Transpl, 1994, 8(5):488-491. ToYODA M, GALFAYAN K, WACHS K, et al. Immunologic monitoring of OKT3 induction therapy in cardiac allograft recipients. Clin Transplant, 1995, 9(6):472-480. SHEREMATA W A, VOLLMER T L, STONE L A, et al. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology, 1999, 52(5):1072-1074. Package Inset. Xolair (omalizumab). New Jersey: Aventis, 2003. BERINSTEIN N L, GRILLO-LOPEZ A J, WHITE C A, et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular nonhodgkin’s lymphoma. Ann Oncol, 1998, 9(9): 995-1001. MALONEY D G, LIES T M, CZERWINSKI D K, et al. phaseⅠclinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood, 1994, 84: 2457-2466. MALONEY D G, GRILLO-LOPEZ A J, BODKIN D J, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphoma. J Clin Oncol, 1997, 15(10): 3266-3274. GORDAN L N, GROW W B, PUSATERI A, et al. Phase II trial of individualized rituximab dosing for patients with CD20-postive lymphoprolife-rative Disorders. J Clin Oncol, 2005, 23(6): 1096-1102. KROP I E, LORUSSO P, MILLER K D, et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol, 2012, 30(26): 3234-324 . HAMIZI S, FREYER G, BAKRIN N, et al. Subcutaneous trastuzumab: Development of a new formulation for treatment of HER2-positive early breast cancer. Onco Targets Ther, 2013, 6:89-94. TSANG R Y, FINN R S. Beyond trastuzumab: novel therapeutic strategies in HER2- positive metastatic breast cancer. Br J Cancer, 2012, 106(1):6-13 . TINOCO G, WARSCH S, GLCK S, et al. Treating breast cancer in the 21st century: emerging biological therapies. J Cancer, 2013, 4(2):117-132. TOKUDA Y, WATANABE T, OMURO Y, et al. Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/ neu-overexpressing metastatic breast cancer. Br J Cancer, 1999, 81(8):1419-1425. OKADA K, YAMASAKI K, TANAKA C, et al. Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors . Jpn J Clin Oncol, 2013, 43(11):1073-1079. GLADE BENDER J L, ADAMSON P C, REID J M, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children′s Oncology Group Study . J Clin Oncol, 2008, 26(3):399-405. GORDON MS, MARGOLIN K, TALPAZ M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer . J Clin Oncol, 2001, 9(3):843-850. GOLAY J, SEMENZATO G, RAMBALDI A, et al. Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. MAbs. 2013, 5(6)826-837. MORSCHHAUSER F A, CARTRON G, THIEBLEMONT C, et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase Ⅱ GAUGUIN study. J Clin Oncol. 2013, 31(23):2912-2919. SEHN L H, ASSOULINE S E, STEWART D A, et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood. 2012, 119(22):5118-25. SALLES G, MORSCHHAUSER F, LAMY T, et al. Phase 1 study results of the type Ⅱ glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood, 2012, 119(22):5126-5132.